Detalhe da pesquisa
1.
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.
Nature
; 586(7830): 567-571, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32756549
2.
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med
; 384(5): 403-416, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33378609
3.
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
N Engl J Med
; 383(20): 1920-1931, 2020 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32663912
4.
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
N Engl J Med
; 383(25): 2427-2438, 2020 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32991794
5.
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
J Virol
; 95(23): e0131321, 2021 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34549975
6.
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
N Engl J Med
; 384(15): 1468-1470, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730471
7.
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.
N Engl J Med
; 384(23): 2259-2261, 2021 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33822494
8.
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
N Engl J Med
; 384(1): 80-82, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33270381
9.
Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors.
Antimicrob Agents Chemother
; 59(10): 6007-16, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26169418
10.
Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.
Antimicrob Agents Chemother
; 59(3): 1569-82, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25547360
11.
Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors.
Bioorg Med Chem Lett
; 25(9): 1990-4, 2015 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25827523
12.
The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials.
Lancet Infect Dis
; 23(5): 621-633, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36682364
13.
An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection.
NPJ Vaccines
; 8(1): 58, 2023 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37080988
14.
An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge.
Sci Transl Med
; 15(716): eadg3540, 2023 10 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37792954
15.
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine - An Interim Analysis.
Res Sq
; 2022 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35547849
16.
A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.
Vaccine
; 39(20): 2791-2799, 2021 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33707061
17.
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants.
bioRxiv
; 2021 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33501442
18.
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
Vaccine
; 39(51): 7394-7400, 2021 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34815117
19.
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
bioRxiv
; 2021 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33880468
20.
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.
Nat Med
; 27(11): 2025-2031, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34526698